Premium Nahrungsergänzungsmittel | artgerecht

Nonne-Milroy-Meige Syndrome – Causes and Treatment

Nonne-Milroy-Meige syndrome is a rare hereditary disorder of the lymphatic system that causes chronic lymphedema, primarily affecting the extremities.

Regular tips about health Regular tips about health

Things worth knowing about "Nonne-Milroy-Meige Syndrome"

Nonne-Milroy-Meige syndrome is a rare hereditary disorder of the lymphatic system that causes chronic lymphedema, primarily affecting the extremities.

What is Nonne-Milroy-Meige Syndrome?

Nonne-Milroy-Meige syndrome refers to a group of hereditary lymphedemas caused by developmental or functional abnormalities of the lymphatic vessel system. It is a rare condition belonging to the category of primary lymphedemas. The syndrome is named after the physicians Max Nonne, William Milroy, and Henri Meige, who were among the first to describe these clinical presentations.

Depending on the age of onset, the syndrome is divided into congenital lymphedema (Milroy disease, present at birth or shortly after) and lymphedema praecox (Meige disease, appearing during puberty or early adulthood).

Causes

The condition is caused by genetic mutations that impair the development and function of lymphatic vessels. In the Milroy form (congenital lymphedema), mutations in the FLT4 gene are frequently identified. This gene encodes vascular endothelial growth factor receptor 3 (VEGFR-3), which plays a critical role in lymphatic vessel growth and maturation.

Autosomal dominant inheritance pattern (in many cases)
Mutations in the FLT4 gene (Milroy form)
Genetic heterogeneity: various genes may be involved
Spontaneous de novo mutations are also possible

Symptoms

The hallmark symptom of Nonne-Milroy-Meige syndrome is chronic lymphedema -- a painless, doughy swelling of the affected tissue caused by an accumulation of lymphatic fluid. The lower extremities are most commonly affected, with the upper extremities or other body regions involved less frequently.

Chronic, painless swelling of the legs and/or arms
Swelling is typically symmetrical
Progressive skin hardening and thickening (fibrosis) over time
Restricted mobility of affected limbs
Increased risk of recurrent skin infections (erysipelas)
Psychosocial impact due to altered physical appearance

Diagnosis

Diagnosis is primarily clinical and is confirmed through additional investigations. A thorough medical history, including a detailed family history, is essential given the rarity of the condition.

Clinical examination: Assessment of swelling, tissue consistency, and distribution of edema
Lymphoscintigraphy: Imaging to evaluate lymphatic vessel function and morphology
MRI or ultrasound: Assessment of soft tissue changes
Genetic testing: Detection of mutations (e.g., in the FLT4 gene)
Differential diagnosis: Exclusion of secondary lymphedema (e.g., due to infection or malignancy)

Treatment

There is currently no curative treatment for Nonne-Milroy-Meige syndrome. Therapy aims to reduce lymphedema, improve quality of life, and prevent complications. Complete decongestive therapy (CDT) is considered the gold standard of treatment.

Conservative Treatment

Manual lymphatic drainage performed by trained therapists
Compression therapy (medical compression stockings or bandages)
Decongestive exercise therapy and physiotherapy
Skin care to prevent infections

Surgical Treatment

Microsurgical lymphatic anastomoses (connecting lymphatic and venous channels)
Lymph node transplantation in selected cases
Reduction surgery in cases of severe tissue overgrowth

Pharmacological Treatment

There is no specifically approved pharmacological therapy. Antibiotics are used in cases of infection (erysipelas). Experimental approaches involving VEGF-C or other growth factors are currently under investigation.

Prognosis and Disease Course

Nonne-Milroy-Meige syndrome is a chronic, lifelong condition. However, with consistent treatment, swelling can be significantly reduced and quality of life substantially improved. Without treatment, there is a risk of progressive tissue fibrosis and recurrent infections.

References

Rockson SG. Lymphedema. Am J Med. 2001;110(4):288-295.
Connell FC et al. The classification and diagnostic algorithm for primary lymphatic dysplasia: an updated proposal from the International Society of Lymphology. Lymphology. 2013;46(2):62-68.
Mortimer PS, Rockson SG. New developments in clinical aspects of lymphatic disease. J Clin Invest. 2014;124(3):915-921.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.